WUNDERKIND
21.5.2024 15:01:26 CEST | Business Wire | Press release
Wunderkind, the leading AI-driven performance marketing solution, today announced the launch of its AI-powered Autonomous Marketing Platform and its first application, Studio, which brings self-service tools to the creative workflow for marketers and services teams.
Wunderkind’s Autonomous Marketing Platform leverages the power of artificial intelligence (AI) to streamline the entire marketing build, report and optimisation process. Through the analysis of trillions of behavioural data points, the platform uncovers valuable insights, facilitating the creation and execution of strategies that drive undeniable performance. The Wunderkind platform delivers on marketing use cases, such as making actionable data available through identity, leveraging AI to deliver omnichannel experiences, measuring insights and integrating with the broader martech ecosystem.
The Autonomous Marketing Platform is underpinned by the Wunderkind Identity Network, a proprietary Identity graph which recognises over 9 billion consumer devices, 1 billion opted-in consumer profiles and observes 2 trillion events per year. This allows Wunderkind to identify up to 50% more consumer profiles than leading email service providers (ESPs), enabling its AI-powered marketing engine to deliver significantly more personalised, 1:1 emails and text messages to drive ROI.
Studio, the First Application in the Platform Roadmap
As the critical marketing infrastructure for more than 700 brands and retailers, Wunderkind’s Studio streamlines the design process to create best-in-class brand experiences for the entire creative process. Studio provides the ability to make real-time creative edits to experiences, which is improving the time to build and launch campaigns by over 50% for Wunderkind clients. The Generative AI (Gen AI) capabilities in Studio empower marketers to quickly optimise their messaging, ensuring optimal conversions based on Wunderkind’s observation across trillions of consumer interactions.
Studio represents a watershed moment for Wunderkind, marking a significant evolution in its AI-driven product vision, which centres on providing adaptive learning and decisioning to proactively elevate marketing performance. Wunderkind’s roadmap includes additional AI-powered applications to further optimise the creation of bespoke customer experiences, robust audience development and deep analytics on engagement and revenue attribution.
This investment in the platform and its connected applications complements Wunderkind’s award-winning managed service offering, which delivers more than $5 billion in guaranteed revenue every year for brands such as Uniqlo, Sonos, Clarks and Kurt Geiger, and typically generates more than 10% of total digital revenue for clients.
“Our Autonomous Marketing Platform brings the full potential of our proprietary data and best practices to scale through AI,” Bill Ingram, CEO at Wunderkind, commented. “Studio significantly reduces the time spent on building marketing creatives and elevating outstanding performance. Wunderkind’s continued investments in AI allows us to deliver dynamic consumer experiences, which drive revenue while guiding brands through massive industry changes.”
Molly Delp, VP of eCommerce and Digital Marketing at skincare brand True Botanicals, commented: “We love Wunderkind because it's a managed service that lets us focus on our day-to-day while their professional services team delivers the engagement and eCommerce revenue lift we need. The launch of Studio brings speed and agility to our revenue strategy”.
Wunderkind will host a virtual public roadmap event on 26 June 2024, which will provide further details on its Autonomous Marketing Platform and other forthcoming applications planned to help marketers drive further enhanced performance and ROI. To register, sign up here.
Notes to editors
About Wunderkind
Wunderkind is the leading AI-driven performance marketing solution that collects consent-based, first-party data and identifies anonymous traffic for brands in order to scale hyper-personalised one-to-one messages. Brands lean on the Wunderkind Identity Network, a proprietary database recognising 9 billion devices and 1 billion opted-in consumers, observing 2 trillion digital transactions per year, to trigger the most impactful offers to their target audience at the right moment and in the right channel. This proprietary data is accessed by Wunderkind's autonomous AI engine, which integrates seamlessly into a brand's existing ESP, to boost performance across email, text and advertising channels.
Wunderkind is the only performance solution that guarantees a lift in revenue for its clients and delivers over $5 billion in directly attributable revenue annually for brands across a number of industries, often ranking as a top 3 revenue channel in clients' own analytics platforms. Brands such as Harley-Davidson, Perry Ellis and Shoe Carnival partner with Wunderkind to drive top-line revenue through its guaranteed results. To learn more, visit wunderkind.co.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521214381/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
